Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn, +23

New England Journal of Medicine

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

James Larkin, Vanna Chiarion‐Sileni, René González, +28

New England Journal of Medicine

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, +21

Science

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Bernard Escudier, Saby George, +23

New England Journal of Medicine

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Alexandra Snyder, Vladimir Makarov, Taha Merghoub, +18

New England Journal of Medicine

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Eliezer M. Van Allen, Diana Miao, Bastian Schilling, +19

Science

Immune EvasionCancer ImmunosurveillanceImmune Checkpoint ActivityMedicineMelanoma +12

An immunogenic personal neoantigen vaccine for patients with melanoma

Patrick A. Ott, Zhuting Hu, Derin B. Keskin, +37

Nature

VaccinationTumor ImmunologyMelanomaImmunologyTherapeutic Vaccine +3

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

Matthew M. Gubin, Xiuli Zhang, Heiko Schuster, +24

Nature

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

Eric Tran, Simon Turcotte, Alena Gros, +10

Science

T-regulatory CellImmunologyPathologyEpithelial CancerImmune Cell Therapy +20

NetMHCpan-4.0: Improved Peptide–MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data

Vanessa Jurtz, Sinu Paul, Massimo Andreatta, +3

The Journal of Immunology

Mhc ClassImmunologyMolecular BiologyAntigen ProcessingPeptide Science +14